AbbVie (MEX:ABBV) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


MEX:ABBV AbbVie Inc MEX:ABBV
72 GF Score
Price MXN4,245.00
GF Value MXN3,691.02
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AbbVie's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:ABBV vs MRK, JNJ, AMGN: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbbVie Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where AbbVie's Margin of Safety % (DCF Earnings Based) falls into.


MEX:ABBV
72GF Score
AbbVie Inc MEX:ABBV
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,245.00 is trading 15% above its estimated GF Value™ of MXN3,691.02. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: MXN3,691.02 vs. price of MXN4,245.00 (15% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score

Get the complete analysis for MEX:ABBV

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,245.00
Price
MXN3,691.02
GF Value